Clinical trial · Observational
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
Containing Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Anti-tumor Treatment of Chinese Patients With Unresectable Locally Advanced / Recurrent or Metastatic Esophageal Cancer: a Real World Study
NCT05349045CI-TRIAL-00058089AIPAAIAECunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Neoplasms | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor group
- interventionNames
- Drug: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
Primary outcomes (1)
- measure
- PFS
- timeFrame
- From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- description
- Progression Free Survival
Secondary outcomes (1)
- measure
- OS
- timeFrame
- From date of admission until the date of death from any cause, assessed up to 24 months
- description
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Esophageal cancer confirmed by histopathology or cytology 2. Unresectable locally advanced/recurrent or metastatic esophageal cancer, or progression after neoadjuvant or adjuvant therapy 3. Esophageal cancer patients who benefit from the use of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor evaluated by the researchers 4. Patients who sign informed consent and voluntarily join the study Exclusion Criteria: 1. Patients who are recommended not using an anti-PD-1/PD-L1 antibody or an angiogenesis inhibitor in the instructions, or other patients who are judged by the investigators to be unsuitable in the study 2. Patients who are undergoing treatment regimen of blind trial
References
Publications (0)
Data not yet available
No reference posted for this study.